Category: Partners

TaxBandits has released a free e-book, “Everything You Need to Know About Form 941,” to help small businesses simplify payroll tax filing and avoid penalties ahead of the July 31 Q2 deadline.

ROCK HILL, SC / ACCESS Newswire / July 30, 2025 / TaxBandits, an IRS-authorized e-file provider, released an informational Form 941 e-book to help small businesses struggling with the administrative burden of payroll taxes to meet the quarter 2 (Q2) Form 941 deadline on July 31.

Titled “Everything You Need to Know About Form 941,” the e-book is now available on the TaxBandits website.

“It can be difficult for small businesses, especially new ones, to learn the ins and outs of payroll taxes and Form 941. With the Q2 deadline this week, we are hearing from a lot of clients who are filing at the last minute. That’s why we created an all-in-one guide to help them understand, prepare, and file Form 941 before the deadline tomorrow,” said CEO of SPAN Enterprises Naga Palanisamy.

How This Guide Helps Businesses Ahead of the Crucial 941 Deadline

Small businesses have many responsibilities to juggle, and adding payroll taxes on top can make meeting deadlines difficult.

• The February 2025 National Small Business Association’s survey reported that 24% of small businesses handle payroll internally and that 10% spend 10 or more hours per month handling payroll taxes.

• And according to the Q2 2025 US Chamber of Commerce Small Business Index, over 40% of small businesses are reporting increased time spent on compliance.

If small businesses are unable to keep up with these burdens and they miss the deadline on July 31, they risk IRS penalties and complications, including 5% of the total tax due for every month the filing is late, up to 25%.

That’s why TaxBandits has released their new e-book, “Everything You Need to Know About Form 941.” It gives business owners a clear path forward-breaking down what to file, when to deposit and how to avoid errors.

Key Information Covered

This e-book concisely breaks down the key areas that are crucial to 941 reporting in six sections, including:

• Overview of Form 941: Explains what information is required on Form 941, who is required to file, and the exceptions.

• Form 941 Tax Deposit Requirements: Details tax deposit requirements based on tax liability, when to deposit the taxes, different deposit schedules, and how to deposit 941 taxes.

• Methods to File Form 941: Explains the differences between e-filing and paper filing and why the IRS recommends e-filing.

• About TaxBandits: Showcases the value in TaxBandits’ 941 e-filing solutions and provides a step-by-step guide on how to e-file Form 941 through TaxBandits.

• Consequences of Failing to Meet the 941 Deadline: Reveals the penalties and risks associated with filing or depositing late.

• How to Correct Errors on a Previously Filed Form 941: Mentions how to correct 941 forms filed with errors by using 941-X.

E-Book Implementation with TaxBandits’ Services

In addition to the e-book, TaxBandits offers a full suite of features designed to help last-minute filers meet today’s deadline with confidence:

• One-click zero reporting: This option allows filers with no tax liability to automatically fill out many fields on the return.
  Prefill functionality: Businesses that have filed before with TaxBandits can copy previous quarter information onto their Q2 return to save time and reduce data entry.

• Error prevention: The platform automatically checks return data against IRS business rules and flags potential issues before submission.
  Schedules included: Schedule B, Form 8974 and Form 941-V are automatically included when applicable. Schedule R is also available for aggregate filers.

• Built-in e-signature tools: Filers can e-sign using Form 8453-EMP or an Online Signature PIN directly within the platform.

• Real-time IRS updates: Businesses receive timely notifications when their return is accepted, rejected or requires further attention.

• No cost corrections: If the filers spot an error after submitting the return, they can make corrections and file a 941-X at no additional cost.

• Free retransmission: If the IRS rejects the form for any errors, filers can fix the errors and retransmit at no additional cost.

• Flexible payment methods: Payment options include Electronic Funds Withdrawal (EFW), EFTPS, credit/debit card or check/money order.

TaxBandits also recognizes that for high-volume filers, such as tax pros and aggregate filers, the deadline represents a significant challenge for gathering, evaluating and submitting large amounts of client data to the IRS.

To support these clients, TaxBandits offers additional features designed for efficiency, including: bulk data upload options, methods for requesting numerous client signatures at once and the ability to apply their e-signature to all client forms simultaneously. Additionally, their team members can be given access to a centralized account for easy task delegation.

“From small businesses to CPA’s filing for dozens of clients, everyone deserves a streamlined 941 filing experience. We will continue to create content like our e-book and our filing solutions so that one day, every filer has this experience,” said Palanisamy.

The e-book “Everything You Need to Know About Form 941” can be downloaded at this link. To file Form 941 before the July 31 deadline, click here.

About TaxBandits

TaxBandits is a SOC 2 Certified, IRS-authorized e-file provider dedicated to providing a simplified filing experience for businesses, service providers and tax professionals of every size. They specialize in Forms 1099, W-2, 940, 941, 1095-B, 1095-C and W-9.

About SPAN Enterprises

SPAN Enterprises is headquartered in Rock Hill, South Carolina, and has been developing industry-leading software tools for e-filing and business management solutions for over a decade. The SPAN portfolio of products includes TaxBandits, ACAwise, ExpressExtension, 123PayStubs and TruckLogics.

Direct all media inquiries to Marketing Manager Caleb Flachman at caleb@spanenterprises.com.

SOURCE: TaxBandits

View the original press release on ACCESS Newswire

The industry report recognizes LHH Recruitment Solutions U.S. for its talent strategy across IT, Engineering and Business & Professionals categories, bringing together staffing, career mobility and technology-upskilling to help organizations build more agile, future-ready workforces.

NEW YORK CITY, NY / ACCESS Newswire / July 30, 2025 / LHH, a global leader in integrated talent solutions and global business unit of the Adecco Group, has been named a Leader in Everest Group’s 2025 PEAK Matrix^® US Contingent Talent and Strategic Solutions 2025 Report for IT, Engineering, and Business and Professionals. Earning the Leader honor in the PEAK Matrix Assessment for the third year in a row, LHH sets the industry standard and continues to invest in innovation to meet the evolving needs of clients and talent throughout the career journey.

LHH Recruitment Solutions offers unmatched expertise and a wide range of services, using interconnected strategies driven by innovation and human care, to strengthen hiring for professional contingent workers. Its proven talent-matching approach integrates advanced technology with large-scale delivery to create tailored solutions for both employers and candidates.

The report explores the contingent staffing provider landscape in the United States and its market impact in 2025 for white-collar workers across IT, Engineering, as well as Business & Professionals industries. Providing the market’s overview and analysis on different contingent talent and strategic solutions providers, LHH Recruitment Solutions is noted as a differentiator based on the Everest Group’s PEAK Matrix evaluation. This marks LHH’s third back-to-back leadership honor in the Everest PEAK Matrix Contingent Talent & Strategic Solutions assessment, as LHH previously ranked a Leader and Star Performer in 2024, and a Leader in 2023.

“This continued recognition highlights the value we are delivering to organizations navigating today’s complex workforce challenges,” said Nicole Gable, President of Recruitment Solutions, North America. “With ongoing talent shortages and a growing demand for flexibility, companies need more than just staffing, they need a partner who can optimize how contingent talent is sourced, managed and deployed with care and quality. Our intentionally developed suite of recruitment solutions, specialized expertise and vast networks, combined with keeping relationships at the heart, sets us apart. By taking a strategic approach that supports workforce agility across the full talent lifecycle, we are helping clients build smarter, more resilient organizations that place talent faster and more consistently.”

“LHH has been named a Leader on Everest Group’s US Business and Professionals Contingent Talent and Strategic Solutions PEAK Matrix Assessment 2025, due to its strong capabilities to source talent across the breadth and depth of skills, including high-skilled professional skills. Its investments in AI-powered tools such as LHH Career Studio enable personalized, data-driven career guidance, while the LHH app simplifies job search and assignment management. Through initiatives such as EZRA and Hire-Train-Deploy model with General Assembly, LHH also demonstrates comprehensive upskilling and reskilling capabilities. Its robust delivery model and access to The Adecco Group’s global infrastructure reinforces its position,” said Priyanka Mitra, Vice President, Everest Group.

As the world of work evolves, LHH Recruitment Solutions supports organizations and professionals at every stage of the talent lifecycle, reshaping the recruitment experience through innovation and impact. With tailored digital career coaching, accessible virtual learning, real-time labor market intelligence and smart AI-enabled resources, LHH empowers people and businesses to adapt with confidence.

Everest Group’s PEAK Matrix is an objective, data-driven evaluation framework of global service providers based on market impact and delivery capabilities. Providers are categorized as Leaders, Major Contenders or Aspirants, with Star Performers recognized for strong year-over-year progress based on performance, innovation and client feedback.

To read the full US Contingent Talent and Strategic Solutions PEAK Matrix Assessment 2025 – IT, Engineering, and Business and Professionals Report, visit the Everest Group website.

###

About LHH

LHH empowers professionals and organizations to achieve bold ambitions and secure lasting impact through unique advisory services and professional talent solutions.

LHH’s full suite of offerings connects solutions that are traditionally siloed, making LHH a single talent partner for organizations. In a rapidly evolving landscape with complex challenges, we create value across the entire professional talent journey. From hiring great people, developing skills and nurturing leaders, to advancing individuals to the next stage of their careers, LHH makes talent a competitive edge.

We believe the future of work lies at the intersection of exceptional human care and innovation. Powered by science, technology, and proprietary data analytics, LHH’s approach is crafted to align with business strategies and cultures, delivering powerful, sustainable, and measurable impact.

LHH has a team of over 12,000 professionals, across 60+ countries and more than 50 years of experience. As part of the Adecco Group, we bring together global excellence, local knowledge and centralized coordination for thousands of companies and millions of people worldwide.

Recruitment. Development. Career Transition.

LHH. A beautiful working world.

To learn more about LHH, visit: lhh.com.

Media Contact
PR@lhh.com

SOURCE: LHH

View the original press release on ACCESS Newswire

LAS VEGAS, NEVADA / ACCESS Newswire / July 30, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) (“ALT5” or the “Company”), a fintech company delivering blockchain-powered payment and trading infrastructure for global merchants and financial institutions, today announced the successful integration of its institutional-grade ALT5 Prime FIX API with Fundamental Interaction, a leading provider of advanced trading technology for U.S. FINRA-registered broker-dealers and Alternative Trading Systems (ATSs).

This integration delivers seamless FIX-based access to digital asset markets directly into the infrastructure trusted by thousands of broker-dealers and trading platforms, representing a significant step toward unifying traditional capital markets with institutional-grade cryptocurrency execution.

“By integrating with Fundamental Interaction’s Real-Time Trading System, we are enabling FINRA-regulated firms to offer secure and compliant access to crypto markets alongside equities and alternatives,” said Peter Tassiopoulos, CEO of ALT5 Sigma Corp. “This is a turnkey pathway for regulated institutions to engage in digital asset trading with the tools, workflows, and auditability they already use.”

Integration Highlights:

• Real-time execution and settlement for BTC, ETH, SOL, and other digital assets

• FIX 4.4 protocol compatibility for routing, clearing, and trade surveillance

• 24/7 crypto market access through the same GUI used for multi-asset equities and ATSs

• KYC/AML and regulatory compliance tools embedded in the trade stack

• Risk management modules for institutional client mandates

Market Context: The FINRA Broker-Dealer Opportunity

There are over 3,300 FINRA-registered broker-dealers in the United States, collectively managing trillions of dollars in assets and facilitating billions of trades annually across equities, fixed income, and alternative assets. According to FINRA’s latest report¹, more than $110 trillion in transaction volume flows through U.S. broker-dealers each year – representing a powerful distribution and execution channel for emerging asset classes like digital assets.

The ALT5-Fundamental Interaction integration provides these institutions with a direct and compliant way to expand their product offerings to include regulated digital asset trading, while maintaining operational efficiency and audit-ready reporting.

“Our clients have asked for a way to integrate digital assets without reinventing their workflow,” said Shawn Sloves, CEO of Fundamental Interaction. “With ALT5 Sigma’s FIX API, they can now offer institutional-grade crypto execution in the same environment they already use for trading equities and alternatives – backed by compliance, risk controls, and market depth.”

¹ Source: 2025-Industry-Snapshot.pdf

About ALT5 Sigma Corporation

ALT5 Sigma Corporation (NASDAQ: ALTS) (FRA: 5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. Since June of 2025, the Company has been a member of the Russell Microcap Growth^®, Russell 3000E^®, and Russell 3000E Growth^®Indexes, as part of the 2025 Russell indexes reconstitution. The Company had previously been included in the Russell Microcap^® Index since June of 2024.

Founded in 2018, ALT5 Sigma, Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) enables the migration to a new global financial paradigm through its suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms: “ALT5 Pay” and “ALT5 Prime.” The company has processed over $5 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

The Company is also advancing the separation of its biotech business, which will continue under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.

About Fundamental Interaction

Fundamental Interaction is a leading trading infrastructure company delivering high-performance technology to broker-dealers, ATSs, and global exchanges. Its Real-Time Trading System supports multi-asset execution, smart routing, risk management, and FIX/REST connectivity with support for both lit and dark venues.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5’s platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5’s services, and technology challenges for future growth or expansion. This press release also may contain statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company‘s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the sections entitled “Risk Factors” in the Company’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media/Investor Relations Contact

IR@alt5sigma.com
1-888-778-7091

SOURCE: ALT5 Sigma Corp

View the original press release on ACCESS Newswire

“Public Enemy No. 1 – Innovation” by Dr. Sebastian Heinz Lifts the Curtain on Why Breakthrough Technologies Stall-and What Must Be Done

NEW YORK, NY / ACCESS Newswire / July 30, 2025 / In a bold and uncompromising address at the Future of Batteries (FOB) Summit 2025, Dr. Sebastian Heinz, CEO of High Performance Battery (HPB), launched his highly anticipated and sharply provocative new book, Public Enemy No. 1 – Innovation.

The book, now available in both English and German, delivers a blistering critique of the forces that actively block innovation in the energy sector and beyond-from entrenched politics to corporate inertia and misguided subsidies. Part memoir, part survival guide, and entirely unflinching, Public Enemy No. 1 is poised to become essential reading for policymakers, investors, founders, and scientists determined to drive progress in the energy transition.

“There is no shortage of brilliant ideas,” said Heinz from the main stage at FOB. “What’s missing is the structural integrity-the operating system-that allows these ideas to scale, survive, and ultimately succeed. This book maps both the obstacles and the exits.”

A Field Guide to the Real Innovation Battlefield

Based on Heinz’s 12-year journey scaling HPB from lab concept to industrial breakthrough, the book blends gritty first-hand experience with sweeping insights on:

• Why “Greed Eats Brains”

• How “Subsidies Go to the Wrong People”

• Why “Friendship Ends With Money”

• And when “The Burn Rate Becomes the Business Plan”

Each chapter is designed as a standalone essay-short, searing, and actionable-making it a pragmatic read for leaders who are done with PowerPoints and press releases, and ready to confront reality.

Timing the Message with a Global Battery Boom

The release couldn’t be timelier. According to Rho Motion, global battery storage installations jumped 53% in 2024, totaling 205 GWh, with North America contributing nearly 40 GWh. SolarPower Europe recently reported that the global solid-state battery market, valued at $98.96 million in 2024, is forecasted to reach $1.36 billion by 2032, expanding at a CAGR of 41.61%.

Despite this growth, Heinz warns: “The real bottleneck isn’t science-it’s the system. And if we don’t fix the system, we’ll watch innovation die in boardrooms, not labs.”

A Wake-Up Call for a Stalled System

The book’s themes align directly with the FOB Summit’s 2025 agenda: “Bridging Innovation: Bringing European Excellence to American Production. “Public Enemy No. 1 – Innovation reframes the conversation around energy transition-not just as a technical challenge, but as an organizational and political one.

Now available in print and online:

Amazon – Public Enemy No. 1 – Innovation

About the Author

Dr. Sebastian Heinz is the CEO and founding member of High Performance Battery Technology GmbH and High Performance Battery Holding AG. A recognized pioneer in sustainable energy storage, Heinz also leads the Institute for Innovation and Cooperation Management (InCoom). His work at the intersection of technology, business model innovation, and policy reform has influenced smart metering, battery systems, and platform-based models for the energy sector.

About High Performance Battery (HPB)

HPB is a European-based battery innovation company redefining solid-state energy storage for scalable, sustainable deployment. With a focus on safety, longevity, and full-cycle sustainability, HPB’s solutions are powering the future of mobility, grid storage, and industrial electrification.

Media Contact:

Monica Brennan
Head of Communications, New to The Street
Monica@NewToTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / July 30, 2025 / Uncorrelated Capital, a new alternative asset investment firm focused on litigation finance and other uncorrelated investment strategies, closed $53 million in funding from a leading private credit fund and one of the nation’s premier plaintiff law firms.

“Litigation finance is one of the most exciting asset classes in the world,” founder Miles Cole said. “We align incentives by investing alongside law firms as partners, rather than lending to them, to drive better outcomes for plaintiffs.”

Uncorrelated is investing in uncorrelated opportunities and has already deployed tens of millions of dollars into thousands of legal claims, including high-profile litigations such as Camp Lejeune.

“Coming from the technology industry, I was shocked by how little software had touched litigation finance,” added Cole. “We’re building the tooling, systems, and infrastructure to further modernize this asset class. Litigation is just the beginning.”

About Uncorrelated Capital

Uncorrelated Capital is an alternative asset investment firm focused on building long-term investments in the world’s most uncorrelated return streams, beginning with litigation finance. The firm partners with leading plaintiff-side law firms to invest in legal claims where outcomes can be improved through better alignment of incentives and long-term capital. Uncorrelated’s broader investment thesis targets niche, uncorrelated opportunities that largely behave independently of a variety of factors including interest rates, equity markets, or macroeconomic cycles, offering exposure to true alternative return streams.

Founded by Miles Cole, a serial entrepreneur who previously founded two venture-backed companies in the medical robotics and fintech sectors, Uncorrelated approaches litigation finance with a long-term, partnership-oriented focus built on alignment of incentives.

Leveraging Cole’s background in technology and venture capital, the firm plans to apply a data-driven, software-first strategy to a sector that has historically been underserved by technology.

To Learn More: Visit www.uncorrelated.capital or email info@uncorrelated.capital.

Media Contact: media@uncorrelated.capital.

SOURCE: Uncorrelated Capital

View the original press release on ACCESS Newswire

JACKSONVILLE, FL / ACCESS Newswire / July 30, 2025 / FRP Holdings, Inc. (NASDAQ:FRPH) anticipates issuing its second quarter earnings results on Wednesday, August 6, 2025. The Company will host a conference call on Thursday, August 7, 2025, at 9:00 a.m. (EDT). Analysts, stockholders and other interested parties may access the teleconference live by calling 1-800-343-4849 (passcode 83364) within the United States. International callers may dial 1-203-518-9848 (passcode 83364). Audio replay will be available until August 21, 2025, by dialing 1-800-839-2385 within the United States. International callers may dial 1-402-220-7203. No passcode needed. An audio replay will also be available on the Company’s investor relations page (https://www.frpdev.com/investor-relations/) following the call.

FRP Holdings, Inc. is a holding company engaged in the real estate business, namely (i) leasing and management of commercial properties owned by the Company, (ii) leasing and management of mining royalty land owned by the Company, (iii) real property acquisition, entitlement, development and construction primarily for apartment, retail, warehouse, and office, (iv) leasing and management of residential apartment buildings.

Investors are cautioned that any statements in this press release which relate to the future are, by their nature, subject to risks and uncertainties that could cause actual results and events to differ materially from those indicated in such forward-looking statements. These include, but are not limited to: the possibility that we may be unable to find appropriate investment opportunities; levels of construction activity in the markets served by our mining properties; demand for flexible warehouse/office facilities in the Baltimore-Washington-Northern Virginia area; demand for apartments in Washington D.C. and Greenville, South Carolina; our ability to obtain zoning and entitlements necessary for property development; the impact of lending and capital market conditions on our liquidity; our ability to finance projects or repay our debt; general real estate investment and development risks; vacancies in our properties; risks associated with developing and managing properties in partnership with others; competition; our ability to renew leases or re-lease spaces as leases expire; illiquidity of real estate investments; bankruptcy or defaults of tenants; the impact of restrictions imposed by our credit facility; the level and volatility of interest rates; environmental liabilities; inflation risks; cybersecurity risks; as well as other risks listed from time to time in our SEC filings; including but not limited to; our annual and quarterly reports. We have no obligation to revise or update any forward-looking statements, other than as imposed by law, as a result of future events or new information. Readers are cautioned not to place undue reliance on such forward-looking statements.

200 W. Forsyth Street, 7th Floor, Jacksonville, FL 32202

Contact:

Matthew C. McNulty
Chief Financial Officer
(904) 858-9100

SOURCE: FRP Holdings, Inc.

View the original press release on ACCESS Newswire

MIAMI, FL / ACCESS Newswire / July 30, 2025 / Safe & Green Holdings Corp. (NASDAQ:SGBX) (“Safe & Green” or the “Company”), a leading developer of modular structures, today announced that it has restructured its previously announced private placement with D. Boral Capital, originally dated April 14, 2025. The revised terms eliminate both the Series A and Series B Common Stock Warrants, significantly reducing potential dilution and addressing the concerns raised by the NASDAQ Hearings Panel.

As a result of the restructuring:

• The Series A Warrants, originally exercisable at $0.784 per share for five years, have been cancelled.

• The Series B Warrants, originally exercisable at $0.98 per share for 30 months, have also been cancelled.

• Overall, the potential dilution to shareholders has been reduced by approximately 70%.

This restructuring conforms with the requirements of the NASDAQ Hearings Panel, which had raised a public interest concern related to the original structure of the transaction. By working closely with NASDAQ and restructuring the deal in a manner that supports both regulatory compliance and investor interests, the Company remains focused on gaining full compliance with NASDAQ listing standards.

“We acted decisively to restructure the financing in a way that better aligns with shareholder interests and ensures full compliance with NASDAQ’s listing standards,” said Mike Mclaren, Chairman and CEO of Safe & Green Holdings. “This is an important step as we continue building long-term shareholder value with a disciplined approach to capital markets activity.”

The Company originally announced the $8.0 million private placement in April 2025, with each Common Unit consisting of one share (or pre-funded warrant), one Series A warrant, and one Series B warrant. With the restructuring, the Common Stock or Pre-Funded Warrants remain in place, while both classes of dilutive warrants have been removed and exchanged for an aggregate of 60,000 shares of Series B Preferred Stock

The Company will continue to evaluate strategic opportunities while remaining focused on responsible governance and disciplined capital management.

About Safe and Green Holdings

Safe & Green Holdings Corp., a leading modular solutions company, operates under core capabilities which include the development, design, and fabrication of modular structures, meeting the demand for safe and green solutions across various industries. The firm supports third-party and in-house developers, architects, builders, and owners in achieving faster execution, greener construction, and buildings of higher value. For more information, visit www.safeandgreenholdings.com and follow us at @SGHcorp on Twitter.

Safe Harbor Statement

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the restructuring of the Company’s private placement with D. Boral Capital. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to maintain compliance with the NASDAQ listing requirements, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

For investor and media inquiries, please contact:
investors@safeandgreenholdings.com

SOURCE: Safe & Green Holdings Corp

View the original press release on ACCESS Newswire

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union.

NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs.

Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval^[1].

The Company also plans to explore a “Fast Track” designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval.

Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later.

Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children.

There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date.

Canada is having a much worse Measles season than the USA, with more than 3,800 cases^[2] to date in 2025.

A Measles holiday warning has been issued in the UK this year^[3]. England itself had more than 3,000 cases of Measles in 2024.

In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children’s Fund (UNICEF)^[4] .

Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO^[5].

A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity (“herd immunity”). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue.

While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine^[6].

Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus.

Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others.

We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

View the original press release on ACCESS Newswire

SIOUX FALLS, SD / ACCESS Newswire / July 30, 2025 / The South Dakota Department of Health in partnership with Avel eCare, a national leader in innovative telemedicine solutions, is proud to introduce a new and uniquely impactful continuing education (CE) credit opportunity for emergency medical services professionals. Beginning August 25, EMS personnel who engage Avel for a telemedicine encounter will be eligible to earn CE credit – marking a first in virtual care.

This CE program has been approved by the South Dakota Board of Medical and Osteopathic Examiners. While the initial rollout is within South Dakota, Avel eCare intends to bring this innovative model to additional states and EMS systems across the country.

“This is more than a new offering, it’s a national first,” said Melissa Magstadt, Secretary of South Dakota Department of Health. “We’re not just improving care in the moment. We’re advancing the careers of EMS professionals, enhancing agency operations, and creating a full-circle support system that sets Avel apart.”

With this model, CE credit is earned in the field, not in a classroom. EMS teams continue to provide patient care while gaining access to expert guidance from Avel’s emergency physicians, paramedics, and nurses. A clinical debrief following the encounter reinforces decision-making and strengthens learning, making education an integrated part of every call.

While this program marks a major innovation, it also addresses a critical challenge in rural EMS: workforce turnover and training fatigue. EMTs and paramedics-many of them volunteers-juggle unpredictable call schedules, demanding clinical responsibilities, and state-mandated continuing education requirements. Traditionally, earning CE credits has meant additional time away from work or family, creating a strain on already overextended teams.

“Our board-certified physicians and experienced paramedics are delivering real-time clinical guidance and now, real-time professional development, all while helping providers stay hands-on with their patients” said Dr. Tyler Price, Medical Director at Avel eCare. “It validates what we’ve known all along – that our virtual interactions aren’t just helpful, they’re educational. We’re training and supporting EMS professionals in real time, with no disruption to the care they’re delivering.”

Through this real-time educational model, EMS personnel gain critical knowledge and confidence while in the field. Clinical support delivered in the back of the ambulance, followed by a brief debrief, reinforces learning in the context of real patient care.

“Avel’s model is not just about connecting clinicians through a screen,” concluded Doug Duskin, CEO of Avel eCare. “It’s about empowering communities with access to the highest level of medical care. And now, we’re extending that impact by offering accredited education, reinforcing our commitment to providers and patients alike.”

About Avel eCare
Avel eCare is a national leader in technology-enabled clinical services delivered through telemedicine, offering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel’s board-certified clinicians partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it’s needed most. Learn more at: www.avelecare.com

Media Contact:
Jessica Gaikowski
Avel eCare
media@avelecare.com

SOURCE: Avel eCare

View the original press release on ACCESS Newswire